LT3504242T - Anti-ox40 antikūnai ir jų panaudojimas - Google Patents
Anti-ox40 antikūnai ir jų panaudojimasInfo
- Publication number
- LT3504242T LT3504242T LTEP17826089.9T LT17826089T LT3504242T LT 3504242 T LT3504242 T LT 3504242T LT 17826089 T LT17826089 T LT 17826089T LT 3504242 T LT3504242 T LT 3504242T
- Authority
- LT
- Lithuania
- Prior art keywords
- antibodies
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3023—Lung
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662434761P | 2016-12-15 | 2016-12-15 | |
| PCT/US2017/066680 WO2018112346A1 (en) | 2016-12-15 | 2017-12-15 | Anti-ox40 antibodies and their uses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LT3504242T true LT3504242T (lt) | 2020-09-10 |
Family
ID=60937946
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTEP17826089.9T LT3504242T (lt) | 2016-12-15 | 2017-12-15 | Anti-ox40 antikūnai ir jų panaudojimas |
Country Status (37)
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112019012328A2 (pt) * | 2016-12-15 | 2019-11-19 | Abbvie Biotherapeutics Inc | anticorpos anti-ox40 e seus usos |
| BR112019025913A2 (pt) * | 2017-06-09 | 2020-06-30 | Glaxosmithkline Intellectual Property Development Limited | métodos para tratar câncer em um paciente em necesssidade do mesmo e para produzir um anticorpo, anticorpo anti-icos ou fragmento de ligação ao antígeno do mesmo e um anticorpo anti-ox40 ou fragmento de ligação ao antígeno do mesmo, uso de um anticorpo anti-icos ou porção de ligação ao antígeno do mesmo e um anticorpo anti-ox40 ou porção de ligação ao antígeno do mesmo na fabricação de um medicamento, polinucleotídeo que codifica um anticorpo, vetor, e, célula hospedeira. |
| US11242398B2 (en) * | 2017-08-01 | 2022-02-08 | Remd Biotherapeutics, Inc. | Anti-OX40 antibodies and methods of activating OX40 |
| CN110790837A (zh) * | 2018-08-02 | 2020-02-14 | 上海君实生物医药科技股份有限公司 | 抗btla抗体 |
| WO2020119789A1 (en) * | 2018-12-14 | 2020-06-18 | Wuxi Biologics (Shanghai) Co., Ltd. | Fully human antibodies against ox40, method for preparing the same, and use thereof |
| WO2020132857A1 (zh) * | 2018-12-25 | 2020-07-02 | 杭州翰思生物医药有限公司 | 抗ox40的单克隆抗体及其应用 |
| CN110172090B (zh) * | 2019-06-03 | 2020-04-03 | 中山标佳生物科技有限公司 | Cd134单克隆抗体及其制备方法和癌症治疗中的应用 |
| WO2021098851A1 (en) * | 2019-11-20 | 2021-05-27 | Eucure (Beijing) Biopharma Co., Ltd | Anti-ctla4/ox40 bispecific antibodies and uses thereof |
| IL293471A (en) | 2019-12-17 | 2022-08-01 | Amgen Inc | Dual interleukin-2 / tnf receptor agonist for use in medicine |
| CN111303285B (zh) * | 2019-12-27 | 2023-06-02 | 百力司康生物医药(杭州)有限公司 | 靶向ox40的抗体及其制备方法和应用 |
| CN113045654A (zh) * | 2019-12-27 | 2021-06-29 | 南开大学 | 抗ox40抗体及其用途 |
| CN113429483A (zh) * | 2020-03-23 | 2021-09-24 | 百奥泰生物制药股份有限公司 | 一种免疫细胞激活剂的开发及应用 |
| PE20230255A1 (es) * | 2020-04-17 | 2023-02-07 | Hutchison Medipharma Ltd | Anticuerpo anti-ox40 y usos del mismo |
| WO2022002009A1 (zh) * | 2020-06-30 | 2022-01-06 | 和铂医药(上海)有限责任公司 | 靶向ox40的抗体及其制备方法和应用 |
| CN116194470B (zh) * | 2020-07-23 | 2025-10-03 | 达因疗法公司 | 肌肉靶向复合物及其用途 |
| CN111704671B (zh) * | 2020-08-19 | 2020-11-24 | 广东赛尔生物科技有限公司 | Ox40抗体及其在治疗癌症中的应用 |
| CN112442121A (zh) * | 2020-08-20 | 2021-03-05 | 山东兴瑞生物科技有限公司 | Ox40抗体、其编码基因、及抗体的制备方法和在增强人体免疫功能中的应用 |
| CN114106173A (zh) * | 2020-08-26 | 2022-03-01 | 上海泰槿生物技术有限公司 | 抗ox40抗体、其药物组合物及应用 |
| CN111763258B (zh) * | 2020-09-01 | 2020-12-29 | 北京百奥赛图基因生物技术有限公司 | 抗ox40抗体及其用途 |
| CN114515335A (zh) * | 2020-11-19 | 2022-05-20 | 百奥泰生物制药股份有限公司 | 抗ox40抗体在治疗肿瘤或癌症中的应用 |
| JP2024508207A (ja) | 2020-12-02 | 2024-02-26 | ブイアイビー ブイゼットダブリュ | がんに対する組み合わせ治療におけるｌｔｂｒアゴニスト |
| WO2022165130A1 (en) * | 2021-01-28 | 2022-08-04 | Astria Therapeutics, Inc. | Plasma kallikrein antibodies and uses thereof |
| CN115260312B (zh) * | 2021-04-30 | 2025-02-14 | 保诺科技（北京）有限公司 | 结合ox40的抗体或抗原结合片段 |
| CN118121694B (zh) * | 2022-12-01 | 2026-03-27 | 北京东方百泰生物科技股份有限公司 | 一种抗Siglec-15单克隆抗体的注射制剂 |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4716111A (en) | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
| US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5413923A (en) | 1989-07-25 | 1995-05-09 | Cell Genesys, Inc. | Homologous recombination for universal donor cells and chimeric mammalian hosts |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| WO1996033735A1 (en) | 1995-04-27 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| DE69120146T2 (de) | 1990-01-12 | 1996-12-12 | Cell Genesys Inc | Erzeugung xenogener antikörper |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| ATE158021T1 (de) | 1990-08-29 | 1997-09-15 | Genpharm Int | Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| PT1024191E (pt) | 1991-12-02 | 2008-12-22 | Medical Res Council | Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5834597A (en) | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| CA2722378C (en) | 1996-12-03 | 2015-02-03 | Amgen Fremont Inc. | Human antibodies that bind tnf.alpha. |
| BRPI9809391B8 (pt) | 1997-04-14 | 2021-05-25 | Amgen Res Munich Gmbh | processo para a produção de um receptor de antígeno anti-humano, anticorpo humano e composição farmacêutica |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| US6312700B1 (en) | 1998-02-24 | 2001-11-06 | Andrew D. Weinberg | Method for enhancing an antigen specific immune response with OX-40L |
| AP1261A (en) | 1998-02-24 | 2004-03-19 | Sisters Of Providence In Oregon | Composition containing an OX-40 receptor binding agent or a nucleic acid encoding the same and methods for enhancing antigen-specific immune response. |
| AU1728800A (en) | 1998-11-18 | 2000-06-05 | Genentech Inc. | Antibody variants with higher binding affinity compared to parent antibodies |
| US7829084B2 (en) | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
| DE60317677T2 (de) | 2002-06-13 | 2008-10-30 | Crucell Holland B.V. | Ox40 (=cd134) rezeptor agonisten und therapeutische verwendung |
| US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| WO2005123780A2 (en) | 2004-04-09 | 2005-12-29 | Protein Design Labs, Inc. | Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis |
| TWI380996B (zh) | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | 抗ｏｘ４０ｌ抗體 |
| AU2005335714B2 (en) | 2004-11-10 | 2012-07-26 | Macrogenics, Inc. | Engineering Fc antibody regions to confer effector function |
| TWI461436B (zh) * | 2005-11-25 | 2014-11-21 | Kyowa Hakko Kirin Co Ltd | 人類ｃｄ１３４（ｏｘ４０）之人類單株抗體及其製造及使用方法 |
| US20080286286A1 (en) | 2006-01-13 | 2008-11-20 | Board Of Regents, The University Of Texas System | Methods to Treat Disease States by Influencing the Signaling of Ox-40-Receptors and High Throughput Screening Methods for Identifying Substances Therefor |
| PT2594590E (pt) | 2007-12-14 | 2015-01-14 | Bristol Myers Squibb Co | Moléculas de ligação ao recetor humano ox40 |
| CA2809089C (en) | 2010-08-23 | 2018-12-18 | Board Of Regents, The University Of Texas System | Anti-ox40 antibodies and methods of using the same |
| CA2845810C (en) * | 2011-08-23 | 2017-03-28 | Board Of Regents, The University Of Texas System | Anti-ox40 antibodies and methods of using the same |
| US20140377253A1 (en) | 2013-03-15 | 2014-12-25 | Abbvie Biotherapeutics Inc. | Fc variants |
| SG10201708048XA (en) * | 2013-03-18 | 2017-10-30 | Biocerox Prod Bv | Humanized anti-cd134 (ox40) antibodies and uses thereof |
| KR20160146747A (ko) | 2014-03-31 | 2016-12-21 | 제넨테크, 인크. | 항혈관신생제 및 ox40 결합 효능제를 포함하는 조합 요법 |
| TW201619200A (zh) | 2014-10-10 | 2016-06-01 | 麥迪紐有限責任公司 | 人類化抗－ｏｘ４０抗體及其用途 |
| WO2016073380A1 (en) | 2014-11-03 | 2016-05-12 | Genentech, Inc. | Method and biomarkers for predicting efficacy and evaluation of an ox40 agonist treatment |
| SG11201708804WA (en) * | 2015-05-07 | 2017-11-29 | Agenus Inc | Anti-ox40 antibodies and methods of use thereof |
| CN114181309B (zh) * | 2015-05-21 | 2024-07-30 | 鳄鱼生物科学公司 | 新型多肽 |
| US20160347848A1 (en) * | 2015-05-28 | 2016-12-01 | Medimmune Limited | Therapeutic combinations and methods for treating neoplasia |
| MA43389A (fr) | 2015-12-02 | 2021-05-12 | Agenus Inc | Anticorps anti-ox40 et leurs procédés d'utilisation |
| BR112019012328A2 (pt) * | 2016-12-15 | 2019-11-19 | Abbvie Biotherapeutics Inc | anticorpos anti-ox40 e seus usos |
-
2017
- 2017-12-15 BR BR112019012328-8A patent/BR112019012328A2/pt not_active Application Discontinuation
- 2017-12-15 KR KR1020197020437A patent/KR102341926B1/ko not_active Expired - Fee Related
- 2017-12-15 DK DK17826089.9T patent/DK3504242T3/da active
- 2017-12-15 RS RS20200923A patent/RS60664B1/sr unknown
- 2017-12-15 US US15/843,281 patent/US10556962B2/en active Active
- 2017-12-15 MY MYPI2019003403A patent/MY198059A/en unknown
- 2017-12-15 PE PE2019001249A patent/PE20191403A1/es unknown
- 2017-12-15 CR CR20190330A patent/CR20190330A/es unknown
- 2017-12-15 BR BR122020025629-0A patent/BR122020025629B1/pt active IP Right Grant
- 2017-12-15 SM SM20200462T patent/SMT202000462T1/it unknown
- 2017-12-15 SI SI201730380T patent/SI3504242T1/sl unknown
- 2017-12-15 RU RU2019121895A patent/RU2753493C2/ru active
- 2017-12-15 CA CA3045940A patent/CA3045940A1/en not_active Abandoned
- 2017-12-15 CN CN201780086610.XA patent/CN110573527A/zh active Pending
- 2017-12-15 HR HRP20201259TT patent/HRP20201259T1/hr unknown
- 2017-12-15 EP EP20173858.0A patent/EP3725809A1/en not_active Withdrawn
- 2017-12-15 MA MA053184A patent/MA53184A/fr unknown
- 2017-12-15 EP EP17826089.9A patent/EP3504242B1/en active Active
- 2017-12-15 PT PT178260899T patent/PT3504242T/pt unknown
- 2017-12-15 MX MX2019007121A patent/MX2019007121A/es unknown
- 2017-12-15 LT LTEP17826089.9T patent/LT3504242T/lt unknown
- 2017-12-15 AR ARP170103527A patent/AR110526A1/es unknown
- 2017-12-15 WO PCT/US2017/066680 patent/WO2018112346A1/en not_active Ceased
- 2017-12-15 UY UY0001037523A patent/UY37523A/es not_active Application Discontinuation
- 2017-12-15 JP JP2019531934A patent/JP6772385B2/ja not_active Expired - Fee Related
- 2017-12-15 HU HUE17826089A patent/HUE050399T2/hu unknown
- 2017-12-15 SG SG10201914126RA patent/SG10201914126RA/en unknown
- 2017-12-15 AU AU2017377036A patent/AU2017377036B2/en not_active Ceased
- 2017-12-15 ES ES17826089T patent/ES2813057T3/es active Active
- 2017-12-15 KR KR1020217041290A patent/KR20210157471A/ko not_active Withdrawn
- 2017-12-15 TW TW106144235A patent/TWI734879B/zh not_active IP Right Cessation
- 2017-12-15 PL PL17826089T patent/PL3504242T3/pl unknown
- 2017-12-15 UA UAA201907981A patent/UA125041C2/uk unknown
-
2018
- 2018-02-28 US US15/908,221 patent/US10040864B2/en active Active
- 2018-08-06 US US16/056,042 patent/US20180346593A1/en not_active Abandoned
-
2019
- 2019-06-03 IL IL267070A patent/IL267070A/en unknown
- 2019-06-13 DO DO2019000165A patent/DOP2019000165A/es unknown
- 2019-06-14 CL CL2019001646A patent/CL2019001646A1/es unknown
- 2019-06-14 PH PH12019501357A patent/PH12019501357A1/en unknown
- 2019-07-08 CO CONC2019/0007288A patent/CO2019007288A2/es unknown
- 2019-07-12 EC ECSENADI201950049A patent/ECSP19050049A/es unknown
- 2019-10-24 US US16/663,131 patent/US10604584B2/en active Active
-
2020
- 2020-02-20 US US16/796,622 patent/US20200181282A1/en not_active Abandoned
- 2020-08-21 CY CY20201100785T patent/CY1123274T1/el unknown
- 2020-09-29 JP JP2020162944A patent/JP2021019603A/ja active Pending
- 2020-10-02 US US17/062,474 patent/US20210017289A1/en not_active Abandoned
-
2021
- 2021-12-23 US US17/560,664 patent/US20220112304A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL267070A (en) | Antibodies against ox40 and their uses | |
| IL283321A (en) | Antibodies against muc16 and their uses | |
| ZA201902265B (en) | Anti-pd-1 antibodies and their uses | |
| IL251537A0 (en) | Human anti-ox40 antibodies and their uses | |
| PL3426686T3 (pl) | Humanizowane przeciwciała anty-pacap i ich zastosowanie | |
| IL258284A (en) | Anti-Lag 3 antibodies and their uses | |
| IL257263A (en) | Antibodies against angptl8 and their use | |
| IL263223A (en) | Antibodies against cd40 and their uses | |
| ZA201901935B (en) | Anti-il-33 antibodies and uses thereof | |
| IL254954A0 (en) | Anti-pacap antibodies and their uses | |
| IL274502A (en) | Anti-OX40 antibodies and uses thereof | |
| PT3292154T (pt) | Anticorpos anti-her3 humano e seus usos | |
| IL266082A (en) | Anti-chikv antibodies and their use | |
| IL266049A (en) | Antibodies against o1 and their uses | |
| GB201503387D0 (en) | Anti-carbapenem antibodies and uses thereof | |
| IL264417A (en) | Anti-o2 antibodies and their uses | |
| IL274202A (en) | Antibodies against Glyco-Moc1 and uses thereof | |
| HK1243094A1 (en) | Humanized anti-ox40 antibodies and uses thereof |